drug

sepiapterin

1 story · latest Jul 30, 2026

Status: FDA approved Jul 2025 · NDA219666
Brand: Sephience
Code: PTC923
Trials: 2 registered trials in coverage

Relationships

Developed by PTC Therapeutics

Timeline

PTC Therapeutics reports Q2 2026 revenue of $361 million, raises full-year guidance

Jul 30Quarterly updatePTC Therapeutics sepiapterin

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.